Amphetamine - Research News and Information

Wednesday, January 07, 2009

D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801.

6 Oct 2008 Since their discovery in the mammalian CNS, D-aspartate and D-serine have aroused a strong interest with regard to their role as putative neuromodulatory molecules. Whereas the functional role of D-serine as an endogenous coagonist of NMDA ... Read more...

Detection of levorotatory methamphetamine and levorotatory amphetamine in urine after ingestion of an overdose of selegiline.

29 Sep 2008 In this study, we measured the urine concentrations of methamphetamine and amphetamine as metabolites of selegiline after ingestion of an overdose of selegiline. A patient who had developed Parkinson disease took selegiline in a suicide attempt. ... Read more...

Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.

31 Aug 2008 OBJECTIVE: Currently there is no approved pharmacotherapy for amphetamine dependence. Recent human laboratory studies have demonstrated that naltrexone modulates some of the reinforcing effects of amphetamine. The aim of this study was to ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Amphetamine'

These are the very latest articles for this heading:

• D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. 6 Oct 2008
• Detection of levorotatory methamphetamine and levorotatory amphetamine in urine after ingestion of an overdose of selegiline. 29 Sep 2008
• Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. 31 Aug 2008
• Simultaneous quantification of amphetamine and methamphetamine in meconium using ISOLUTE HM-N-supported liquid extraction columns and GC-MS. 30 Aug 2008
• Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. 25 Aug 2008
• Electrical stimulation modulates the amphetamine-induced hemodynamic changes: an fMRI study to compare the effect of stimulating locations and frequencies on rats. 13 Aug 2008
• Inhibition of CaMKII in the nucleus accumbens shell decreases enhanced amphetamine intake in sensitized rats. 5 Aug 2008
• Acceleration tolerance at night with acute fatigue and stimulants. 30 Jul 2008
• Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: a mechanism of behavioral sensitization. 28 Jul 2008
• Prenatal restraint stress differentially modifies basal and stimulated dopamine and noradrenaline release in the nucleus accumbens shell: an 'in vivo' microdialysis study in adolescent and young adult rats. 28 Jul 2008
• Amphetamine exposure enhances accumbal responses to reward-predictive stimuli in a pavlovian conditioned approach task. 21 Jul 2008
• Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice. 17 Jul 2008
• Delta FosB mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure. 14 Jul 2008
• Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. 13 Jul 2008
• Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. 8 Jul 2008
• Feeding conditions differentially affect the neurochemical and behavioral effects of dopaminergic drugs in male rats. 8 Jul 2008
• Anomalous dopamine release associated with a human dopamine transporter coding variant. 7 Jul 2008
• Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine- and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase. 7 Jul 2008
• Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. 30 Jun 2008
• Chronic social stress in adolescence influenced both amphetamine conditioned place preference and locomotor sensitization. 29 Jun 2008

See a longer list of these articles.

Technical information about 'Amphetamine'

Definition: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.

Chemical name: Benzeneethanamine, alpha-methyl-, (+-)-

Registry Number: 300-62-9

Descriptor UI: D000661

Alternative terms: Amphetamine; Phenopromin; Phenamine; Amfetamine; Desoxynorephedrin; Fenamine; Centramina; Miquel Brand of Amfetamine Sulfate; Mydrial; Thyramine; Amphetamine Sulfate; Sulfate, Amphetamine; Amphetamine Sulfate (2:1); l-Amphetamine; l Amphetamine; Levoamphetamine; levo-Amphetamine; levo Amphetamine;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Central Nervous System Stimulants; Sympathomimetics; Dopamine Agents; Adrenergic Agents; Adrenergic Uptake Inhibitors; Dopamine Uptake Inhibitors;

Tree Number: D02.092.471.683.152.110;

Technical Notes: a specific chem: do not confuse with AMPHETAMINES; d-amphetamine = DEXTROAMPHETAMINE; N-methylamphetamine = METHAMPHETAMINE